FAQ on the Delta Plus variants of the SARS-Cov-2 virus

Q. Why does a virus mutate?

Virus by its very nature mutates. It is part of its evolution. The SARS-Cov-2 virus is a single-stranded RNA virus. So, changes in the genetic sequence of the RNA are mutations. The moment a virus enters its host cell or a susceptible body, it starts replicating. When the spread of infection increases, the rate of replication also increases. A virus that has got a mutation in it is known as a variant.

Q. What is the impact of mutations?

The normal process of mutations begins to impact us when it leads to changes in transmission levels or on treatment. Mutations can have positive, negative or neutral effects on human health.

Negative impacts include clustering of infections, increased transmissibility, ability to escape immunity and infect someone who has prior immunity, neutralization escape from monoclonal antibodies, improved binding to lung cells and increased severity of infection.

Positive impacts can be that the virus becomes non-viable.

Q. Why are frequent mutations seen in the SARS-CoV-2 virus? When will the mutations stop?
SARS-CoV-2 can mutate due to the following reasons:

·Random error during replication of the virus

·Immune pressure faced by viruses after treatments such as convalescent plasma, vaccination or monoclonal antibodies (antibodies produced by a single clone of cells with identical antibody molecules)

·Uninterrupted transmission due to lack of COVID-appropriate behaviour. Here the virus finds an excellent host to grow and becomes more fit and more transmissible.

The virus will continue to mutate as long as the pandemic remains. This makes it all the more crucial to follow COVID appropriate behaviour.

 Q.  What are Variants of Interest (VoI) and Variants of Concern (VoC)?

When the mutations happen – if there is any previous association with any other similar variant that is felt to impact public health – then it becomes a Variant under Investigation.

Once genetic markers are identified which can have an association with receptor binding domain or which have an implication on antibodies or neutralizing assays, we start calling them Variants of Interest.

The moment we get evidence for increased transmission through field-site and clinical correlations, it becomes a Variant of Concern. Variants of concern are those that have one or more of the following characteristics:

• Increased transmissibility
• Change in virulence/ disease presentation
• Evading the diagnostics, drugs and vaccines

The 1st Variant of Concern was announced by the UK where it was found. Currently, the scientists identified four variants of concern - Alpha, Beta, Gamma and Delta.

 Q. What are Delta and Delta Plus variants?

These are the names given to variants of the SARS-CoV-2 virus, based on the mutations found in them. WHO has recommended using letters of the Greek Alphabet, i.e., Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617), etc., to denote variants, for easier public understanding.

Delta variant, also known as SARS-CoV-2 B.1.617, has about 15-17 mutations. It was first reported in October 2020. More than 60% of cases in Maharashtra in February 2021 pertained to delta variants.

It is the Indian scientists who identified the Delta Variant and submitted it to the global database. Delta variant is classified as a Variant of Concern and has now spread to 80 countries, as per WHO.

Delta variant (B.1.617) has three subtypes B1.617.1, B.1.617.2 and B.1.617.3, among which B.1.617.1 and B.1.617.3 have been classified as Variant of Interest, while B.1.617.2 (Delta Plus) has been classified as a Variant of Concern.

The Delta Plus variant has an additional mutation in comparison to the Delta variant; this mutation has been named the K417N mutation. ‘Plus’ means an additional mutation has happened to the Delta variant. It does not mean that the Delta Plus variant is more severe or highly transmissible than the Delta variant.

 Q. Why has the Delta Plus Variant (B.1.617.2) been classified as a Variant of Concern?

The Delta Plus variant has been classified as a Variant of Concern because of the following characteristics:

• Increased transmissibility
• Stronger binding to receptors of lung cells
• Potential reduction in monoclonal antibody response
• Potential post-vaccination immune escape

 Q. How often are these mutations studied in India?

Indian SARS-CoV-2 Genomics Consortium (INSACOG) coordinated by the Department of Biotechnology (DBT) along with Union Health Ministry, ICMR, and CSIR monitor the genomic variations in the SARS-CoV-2 regularly through a pan India multi-laboratory network. It was set up with 10 National Labs in December 2020 and has been expanded to 28 labs and 300 sentinel sites from where genomic samples are collected. The INSACOG hospital network looks at samples and informs INSACOG about the severity, clinical correlation, breakthrough infections and re-infections.

More than 65,000 samples have been taken from states and processed, while nearly 50,000 samples have been analysed of which 50% have been reported to be Variants of Concern. 

Q. On what basis are the samples subjected to Genome Sequencing?

Sample selection is done under three broad categories:

1. International passengers (during the beginning of the Pandemic)
2. Community surveillance (where RT-PCR samples report CT Value less than 25)
3. Sentinel surveillance - Samples are obtained from labs (to check transmission) and hospitals (to check severity)

When there is any public health impact noticed because of genetic mutation, then the same is monitored.

 Q. What is the trend of Variants of Concern circulating in India?

As per the latest data, 90% of samples tested have been found to have Delta Variants (B.1.617). However, the B.1.1.7 strain which was the most prevalent variant in India in the initial days of the pandemic has decreased.

Q. Why public health action is not taken immediately after noticing mutations in the virus?

It is not possible to say whether the mutations noticed will increase transmission. Also, until there is scientific evidence that proves a correlation between the rising number of cases and variant proportion, we cannot confirm there is a surge in the particular variant. Once mutations are found, analysis is made week on week to find if there is any such correlation between the surge of cases and variant proportion. Public health action can be taken only after scientific proofs for such correlation are available.

Once such correlation is established, this will help prepare in advance when such a variant is seen in another area/region.

 Q. Do COVISHIELD and COVAXIN work against the variants of SARS-CoV-2?

Yes, COVISHIELD and COVAXIN are both effective against the Alpha, Beta, Gamma and Delta variants. Lab tests to check vaccine effectiveness on Delta Plus Variant are ongoing.

Delta Plus Variants: The virus has been isolated and is being cultured now at ICMR’s National Institute of Virology, Pune. Laboratory tests to check vaccine effectiveness are ongoing and the results will be available in 7 to 10 days. This will be the first result in the world.

Q. What are the public health interventions being carried out to tackle these variants?

The public health interventions needed are the same, irrespective of the variants. The following measures are being taken:

• Cluster containment
• Isolation & Treatment of cases
• Quarantining of contacts
• Ramping up vaccination

Q. Do public health strategies change as the virus mutates and more variants arise?

No, public health prevention strategies do not change with variants.

Q. Why is continuous monitoring of mutations important?

Continuous monitoring of mutations is important to track potential vaccine escape, increased transmissibility and disease severity.

Q. What does a common man do to protect him/her from these Variants of Concern?

One must follow COVID Appropriate Behaviour, which includes wearing a mask properly, washing hands frequently and maintaining social distancing.

The second wave is not over yet. It is possible to prevent a big third wave provided individuals and society practise protective behaviour.

Further, Test Positivity Rate must be closely monitored by each district. If the test positivity goes above 5%, strict restrictions must be imposed.